# Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease

> **NCT01509677** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 158 (actual)

## Conditions studied

- COPD
- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01509677
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-01
- **Primary completion:** 2016-02-01
- **Final completion:** 2016-02-01
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2019-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01509677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01509677, "Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01509677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*